GLPG4716
GLPG4716 is a novel, small molecule CHIT1/AMCase dual-inhibitor targeting a key pathway implicated in inflammation and tissue remodeling. Increased chitinase activity has been observed in several inflammatory, fibrotic diseases. We in-licensed GLPG4716 from OncoArendi in November 2020 which we are planning to start a Phase 2 study in lung fibrosis.
GLPG4716
A chitinase inhibitor inlicensed from Molecure (previously OncoArendi). The rights to the molecule have been returned to Molecure in July 2022